Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825

Blood. 2006 Jun 1;107(11):4571-2. doi: 10.1182/blood-2005-11-4707.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Dasatinib
  • Humans
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Pyrimidines / therapeutic use*
  • Remission Induction / methods
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Thiazoles / therapeutic use*

Substances

  • Pyrimidines
  • Thiazoles
  • Dasatinib